Nuwellis Advances Aquadex Label Expansion for Pediatric Use After Successful FDA Pre-Submission
NUWE is trading near its 52-week low of $0.96 (9.4% above the low).
Summary
Nuwellis, Inc. announced the successful completion of a pre-submission meeting with the FDA regarding the proposed label expansion of its Aquadex SmartFlow® System. This expansion aims to include pediatric patients weighing 5 kg and above, significantly broadening the addressable market from the current 20 kg and above indication. This positive regulatory step provides clarity on the pathway for a 510(k) submission, which the company anticipates by the end of 2026. For a medical technology company facing a going concern warning and recent Q1 losses, this development is crucial as it targets a high-need patient population and represents a significant growth opportunity for a core product. Traders will monitor the progress of the 510(k) submission as a key catalyst for future revenue.
At the time of this announcement, NUWE was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.96 to $43.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.